Interpace Biosciences, Inc.

IDXG

US46062X3035

Managed Healthcare

Delayed OTC Markets Other stock markets 11:29:59 2024-06-04 am EDT			5-day change	1st Jan Change
1.5 ^USD	-3.23%		-3.23%	+38.89%

02:00pm	Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 Abstract	CI
May. 09	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Interpace Diagnostics Group, Inc. Provides Revenue Guidance for the Year 2019

May 13, 2019 at 04:05 pm EDT

Interpace Diagnostics Group, Inc. provided revenue guidance for the year 2019. The company is providing annual net revenue guidance of between $27 million and $28 million, representing an approximate 25% increase over 2018.

Latest news about Interpace Biosciences, Inc.

Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 Abstract	08:00am	CI
Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M	Mar. 07	MT
Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Robert Gorman Provides Notice to Interpace Biosciences, Inc. of His Resignation as A Director and as Chairman of the Board, Including as A Member of the Board?s Regulatory Compliance Committee	Dec. 12	CI
Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director	Nov. 16	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Interpace Biosciences, Inc. Enters Amendment to Loan Security Agreement with Broadoak Fund V, L.P	23-10-27	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Chief Financial Officer	23-08-02	CI
Interpace Biosciences, Inc. Expects to Stop Offering Pancragen Test Due to CMS Decision to End Reimbursement as of July 17, 2023	23-06-05	CI
Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q1 Revenue $9.8M	23-05-12	MT
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Principal Financial Officer	23-04-25	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-27	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-27	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $8.3M	23-03-27	MT
Interpace Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	23-03-26	CI
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q3 Revenue $8.19M	22-11-14	MT
Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Interpace Biosciences CFO Thomas Freeburg Resigns	22-10-04	MT
Interpace Biosciences, Inc. Announces Resignation of Thomas Freeburg as Chief Financial Officer	22-10-04	CI
Interpace Biosciences, Inc. Announces New Clinical Validation Data	22-09-01	CI

Chart Interpace Biosciences, Inc.

Duration

Period

More charts

Company Profile

Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.

Sector

Managed Healthcare

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company